Literature DB >> 7128371

The management of acquired rectourinary fistula.

J S Thompson, D E Engen, R W Beart, C E Culp.   

Abstract

Rectourinary fistula is an uncommon entity with many causes for which the optimal management remains unclear. To clarify this, a 50-year experience with acquired rectourinary fistula at the Mayo Clinic was reviewed. In the management of 57 patients, 34 patients underwent repair of rectourinary fistula, the success rate being 88 per cent and the morbidity 29 per cent. Based on this experience, a simple plan of management emphasizing etiologic and prognostic factors is presented. Repair of rectourinary fistulas can be undertaken with a high degree of success and acceptable morbidity for patients with fistulas of benign cause and for those with fistulas of malignant cause who have no gross evidence of malignancy, minimal induration from irradiation, and anticipated long-term survival. Colostomy as an adjunctive procedure is usually unnecessary in the repair of fistulas associated with benign conditions.

Entities:  

Mesh:

Year:  1982        PMID: 7128371     DOI: 10.1007/bf02629542

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  3 in total

1.  Rectal complications after modern radiation for prostate cancer: a colorectal surgical challenge.

Authors:  David W Larson; Kristin Chrouser; Tonia Young-Fadok; Heidi Nelson
Journal:  J Gastrointest Surg       Date:  2005-04       Impact factor: 3.452

2.  Technique de York-Mason dans le traitement des fistules prostato-rectales (à propos de trois cas) : Technique et synthèse de la littérature.

Authors:  Anass Nouri; Souhail El Yacoubi; Anas Daoudi; Tarek Karmouni; Khaled El Kahder; Abdellatif Koutani; Ahmed Ibn Attya; Mohamed Hachimi
Journal:  Can Urol Assoc J       Date:  2012-08       Impact factor: 1.862

Review 3.  Management of rectourethral fistulas in Crohn's disease.

Authors:  G A Santoro; L Bucci; F A Frizelle
Journal:  Int J Colorectal Dis       Date:  1995       Impact factor: 2.571

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.